On Haiti — And Syria — And Removals, Attempted By Tangerine 2.0: At The Supremes

There will be expedited briefing, and a one hour argument at the Supremes in April, to resolve whether Trump can avoid the lower courts’ rulings holding that he cannot, with a Sharpie alone, revoke the temporary protected status of asylum seekers from Syria and Haiti.

Do read all of this. It accurately sets out the black letter law. Trump will lose [the animation at right depicts the last major hurricane — Melissa — to strike Haiti]:

…The government will suffer no irreparable harm if the district court’s order remains in effect pending the government’s appeal of it. Haiti has been designated for Temporary Protected Status since 2010. Since then, hundreds of thousands of Haitian TPS holders have lived in and contributed to American communities across the country. The government identifies no emergency requiring their immediate expulsion….

Respondents, by contrast, will suffer irreparable — potentially fatal — injury if the district court’s order is stayed.

Respondents would be subject to immediate detention and removal to Haiti, “a maelstrom of disease, poverty, violence (including sexual violence) and death.” Indeed, the State Department (Editorial note: at least, as imagined by the MAGAts now in control of it) advises that you should not travel to Haiti for any reason but that if you nevertheless do, then you should “[l]eave DNA samples with your medical provider and dental records with your family in case it is necessary for your family to access them to identify your remains.”

It is, moreover, respondents rather than the government who are likely to prevail on the merits….

Since the assassination of President Jovenel Moïse in 2021, armed gangs have gained control over much of [Haiti’s capital] Port-au-Prince, creating a power vacuum that has made governing a challenge and fueled further violence, homelessness and starvation. More than 5,600 people were killed and 1,400 were kidnapped amid gang conflicts last year, according to the United Nations. The violence has rendered 1 million people homeless in Haiti, forcing many into makeshift shelters and exacerbating the country’s economic challenges….

Onward, resolutely.

नमस्ते

Spreading The Time Between Ebola Vaccine Receipt, And Booster(s) Improves Overall Antibody Response…

Just a quick Friday squib (since my men’s brackets are busted)… as I head down, out of the high mountains — to potentially 90 degree weather in Boulder tomorrow(!).

It comes from a well-respected source: The Journal of Nature — and we see that delaying the time for a booster of the Ebola vaccine improves the robustness of the human body’s antibody production — yes, this is power alley stuff. Do take a gander:

…Here, we elucidated the longitudinal humoral immune repertoire over 3 years following prime and boost rVSV∆G-ZEBOV-GP vaccinations administered 18 months apart in healthy adults compared to participants randomized to no boost. This delayed booster vaccination induced long-lasting EBOV-neutralizing antibodies that persisted up to 36 month at levels similar to peak titers after a single dose. Phage display libraries, expressing linear and conformational epitopes of EBOV glycoprotein (GP), demonstrated a highly diverse and durable antibody epitope repertoire following prime boost vaccination. Delayed booster vaccination recalled memory B cells, promoted anti-GP IgG class switching and induced antibodies specific to GP with Fcγ receptor interaction and functional antibody-dependent cellular cytotoxicity and phagocytosis.

The 18-month interval led to 13-fold higher antibody affinity maturation than a single dose, maintained up to 36 months. Overall, delayed rVSV∆G-ZEBOV-GP booster vaccination promoted a diverse, stronger, durable, predominant IgG, highly affinity-matured antibody response to GP….

Onward, grinning. And, here’s to hoping my CU Buffs’ women hoopsters are able to take down the mighty Illini, tomorrow night. Be excellent to one another.

नमस्ते

[U — 03.19.26 @ 8 AM Mountain] My Third (Mostly Trivial) Passion…

Perhaps it is not as trivial as I might have initially thought, in so far as BHO 44 shows us that there is still much light, laughter and infectious joy — in this rather dark epoch — of Tangerine 2.0.

Second Update @ 10 PM on 3.19: It seems that my brackets are likely already busted — at the end of night one — since North Carolina lost — and the Badgers did too, to High Point (who?!) in pathetic fashion. Sadly, I had UNC to go on to beat Illinois.

Mr. Obama did not make that mistake. But he does have Mizzou to win over Miami tomorrow. Now, if I can take that one from him, I might still have a chance. Overall, though I am highly unlikely to win any of the pools I am in (six of them), since Wisconsin also lost. End second update.

Indeed, I’ve stayed up late working on my brackets in large part because Mr. Obama (the cad!) forever discloses his at the last moment — this time, coming after 6 PM Eastern time when brackets close at noon Eastern tomorrow. In now two long decades, I’ve only ever beaten him three times. Updated 8 am Mountain 03.19.26: Here are the final brackets; with my differences from Mr. Obama in green (click to embiggify):

[I suppose it would be more truthful to say that my mountain based charge here had fallen asleep — and so I was then free to work on it.] At the moment, I’m thinking Houston or Duke, while he sees Arizona as the men’s champion. Hmmm. We both agree it is UConn — on the women’s brackets. [I do think Colorado’s Lady Buffs might upset a power-packed Illini squad, while Mr. Obama makes a safe pick there and chooses Illinois.]

S M I L E — mine (the full braketology) will post mañana!

नमस्ते

As The Two Begin Mediation, Merck (US) Seeks Updated Financial Performance Information, From The German Merck…

We recently hailed — as very good news — the disclosure in court that these two massive international public companies were set to conduct a mediation with a preeminent but retired federal judge “as referee“, to try to work out a “win/win” settlement — without a “winner take all” federal Lanham Act trial in the NJ federal courts, and high likelihood of… truly jaw-slacking damages — for one of the parties.

To make those discussions meaningful, both sides need to know just how much the other is making in the US off of the name, wordmark and branding called “Merck” — as two separate companies are employing the same one. Here’s that request, from the US company, for updated US finanacial performance info, and a bit:

…Merck’s request is simple and falls squarely within the heartland of Federal Civil Procedure Rule 26(e). Merck asks only that defendant Merck KGaA (“KGaA”) update the documentary evidence (compiled in four spreadsheets) that it previously produced concerning its sales and expenses in the United States. This information is relevant to Merck’s request to recover “defendant’s profits” as “compensation” for KGaA’s misconduct, as the Lanham Act expressly authorizes the Court to grant. 15 U.S.C. § 1117(a). Merck’s request is fully consistent with ordinary litigation practice. Damages numbers are routinely brought forward in intellectual property cases before trial to avoid giving a defendant a free pass for misconduct in the period since the close of discovery. The information requested is entirely within KGaA’s control. It is routine business information of a kind that KGaA already has produced, and that both sides’ experts have already used to calculate KGaA’s U.S. profits….

KGaA’s representation that Merck has not alleged continuing harm (ECF No. 320 at 30:21-22) is belied by the Pretrial Order. For example, Merck’s Disputed Facts section on liability emphasized the continuing nature of KGaA’s misuses, and the harm it causes Merck. See, e.g., ECF No. 311 at 73 ¶ 72 (“Defendant’s intentional illegal use of the ‘Merck’ name has caused and will cause continue to cause irreparable and ongoing harm to Plaintiffs’ trademarks, reputation, goodwill, and business in the future…. This harm is ongoing and capable of being repeated.”). In the damages section, Merck stated that its reported disgorgement calculations are understated due to the limited scope of KGaA’s prior financial disclosures. See id. at 76 ¶ 4 (“These numbers are limited by the financial data that Defendant produced through fact discovery, and do not reflect additional damages incurred due to Defendant’s unlawful rebranding to date.”). These points are not new: Merck has always maintained that KGaA’s misuse is continuing….

Merck respectfully requests the Court order KGaA to produce updated U.S. sales and expenses figures to complete its production of “[d]ocuments sufficient to show, on a monthly basis, the marginal costs, fixed costs, and profit margins for each of the goods or services sold in the United States by or on behalf of Defendant since January 1, 2006….”

Now you know, Condor predicts this letter motion will be granted. And so — onward — with summer-like weather here at elevation: gonna’ be in the 70s today, while it was below 18, with deep snow, until just two days ago. Blue skies ahead… Woot!

नमस्ते

Two (Or Three) Abiding — If Trivial — Passions, This Morning: 3.14159 (Belated) And The Saint… Remembered.

No health care, life science, space science, STEM, R&B or constitutional law and politics — on this particularly fine sunny soon to be 65 degree Tuesday in the Rockies.

Nope.

And if you must, go get a wedge of cherry-, or your favorite… pie — on lunch (we missed it while in the air on last Saturday).

Of course by Thursday morning, we will also post our bracketology — as compared to that of BHO 44. Onward, grinning… ever, grinning. Be excellent to one another.

नमस्ते

Just A Monday Squib, Confirming My Lilly Analysis… Looks Good, Through 2029, At Least. Get It While It Is Below $1,000…

As we mentioned yesterday (but of course, do your own due diligence here!), Lilly has been on a nice-heater, with the weight-loss franchises — and now it is set to market an oral weight loss challenger, to compete with Novo-, as early as Q2 2026.

That bodes well for Lilly though at least 2029. Here’s that blurb — and yes this is power alley stuff, but I don’t follow the weight loss drugs closely — as I am a lil’ concerned about potential longer-term side effects. [All of which we just haven’t seen the drugs on mass-market long enough — to really get a read-out on. Like over several hundred thousands of patients, over a decade, or more — and we are still about four years away from having that longitudinal data, post hoc.]

…After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the one arena it now dominates — oral therapeutics. But with Lilly preparing to launch its obesity pill orforglipron as early as the second quarter, can Novo’s grip on the oral market last?

This year got off to a rocky start for the Danish pharma giant. The company said last month it’s expecting a drop in sales and profits in 2026 as it faces federal pricing constraints, and fierce competition from Lilly and compounding pharmacies….

Now you know — from snow yesterday to mid-60s later today and bright sunshine! Welcome to Spring weather in the Rockies. Heh….

नमस्ते

The Final Leg Of This Series (For Now): The Smaller Lilly Spend — In 2025…

Since I am mostly out of pocket this week — we will wait to detail the Amazon spend until around the middle of the following week.

And as you can see, Lilly tends to spend less than the other majors, concentrating its efforts on the preserving and defending its blockbuster weight-loss franchises:

…Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs….

Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the “Inflation Reduction Act” (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)….

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the “Inflation Reduction Act” (HR.5376); CMS National Coverage Determination on Alzheimer’s disease; One Big Beautiful Bill Act (HR.1)….

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality….

Pharmaceutical intellectual property issues….

Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)….

Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act….

Snow… now, all shoveled, but it is still drifting down in big wheeling flakes, here… almost lazily. Heh.

नमस्ते

“The Big Apple” Now Sees First Clade 1b Case Of Mpox — Travel-Related; But Do Be Cautious!

This strain of mpox is the one to be most concerned about. It is generally associated with the severe symptoms, upon taking hold in a host human.

So, as so many others — including this outlet have said — the 12 or so months since Trump cut USAID funding off… has led, and will continue to lead, to entirely avoidable adverse public health consequences, even here at home — right in Manhattan:

…New York City health officials have confirmed the city’s first case of a more severe strain of the mpox virus than the one that drove a global outbreak in 2022.

The case is travel-related, and the city’s Department of Health said there is no known local transmission at this time.

Mpox, formerly known as monkeypox, spreads through close or intimate contact, including hugging or cuddling. It’s not classified as a sexually transmitted infection, but in the United States the disease has primarily spread among the LGBTQ+ community through sex between men and other forms of close contact….

Onward — and although it was sunny and 70, yesterday — I’ve got about three inches of new white stuff to shovel this morning, at 8,500 feet. A real live Currier & Ives affair. Grin….

नमस्ते

And Next — Check Out The Mega-Lobby-Spending, By Amgen, Over Last Three Years…

As with the others, the figures are annual, but the text describes only Q4 2025 activity — for earlier periods, just search the words “lobby spend” in the search dialogue box.

Amgen has really taken the lead dog role, in spending — right behind the overall pharma trade association, as a group (PhRMA). Here’s a sample of what they jaw-boned Congreass about — in Q4 2025:

…Issues related to drug pricing; Issues related to cardiovascular disease awareness and treatment; Issues related to FDA; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Issues related to biosimilars reimbursement; Issues related to Supply Chain; Issues related to 340B; Issues related to pharmacy benefit managers; Issues related to biosimilars regulatory standards; Issues related to bone disease awareness and treatment; Issues related to Public law 117-1769 Inflation Reduction Act; Issues pertaining to the implementation of PL 97-414 “Orphan Drug Act,” all provisions; HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); S 1954 Biosimilar Red Tape Elimination Act; HR 5526 Biosimilar Red Tape Elimination Act; HR 2214 DRUG Act; H.R.1968 – Full-Year Continuing Appropriations and Extensions Act, 2025; HR 5509 Safe Step Act; HR 5256 340B Access Act; HR 4581 340B Patients Act; S 2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act; H.R. 6703 Lower Health Care Premiums for All Americans Act; S 3345 PBM Price Transparency and Accountability Act; H.R. 6166 Lowering Drug Costs for American Families Act; S.3019 No Big Blockbuster Bailouts Act; H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients
S 3349 PBM Disclosure Act; HR 4317 PBM Reform Act; S 3510 Biosimilar Inspection Modernization Act….

Issues related to drug pricing; Issues related to Public law 117-1769 Inflation Reduction Act; Issues related to cardiovascular disease awareness and treatment; Issues related to reimbursement for biologics/biosimilars; Issues related to PBM reform; Issues related to bone disease awareness and treatment — HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); H.R.1968 – Full-Year Continuing; Appropriations and Extensions Act, 2025; S.3345, PBM Price Transparency and Accountability Act; H.R. 6166, Lowering Drug Costs for American Families Act; S.3019 – No Big Blockbuster Bailouts Act; H.Res. 928 – Affirming support for most-favored-Nation drug pricing for United States patients; S 3349 PBM Disclosure Act; HR 4317 PBM Reform Act….

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income; Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); Issues related to patents and taxes….

Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to patent thickets/product hopping; Issues related to obviousness/ double patenting; Issues related to FDA/PTO coordination; Issues related to skinny labeling; Issues related to patents and taxes; S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; S.1040 — A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; S.2296– NDAA (FY 2026 National Defense Authorization Act — BIOSECURE language); S 708/ HR 1574 — Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE); S.1553/HR3160 — Promoting and Respecting Economically Viable American Innovation Act (PREVAIL); S. 1546/ HR 3152– Patent Eligibility Restoration Act of 2025 (PERA); S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act); HR 6485 Skinny Labels Big Saving Act….

There you have it. Onward — with big winds — and snow, ahead! Grin….

नमस्ते

By This Hinderaker Means… He Doesn’t Believe In… Due Process. At All. Except For… For His Friends.

John complains that the specious attempt by MAGA-nuts at DoJ, to make the Fed Chair criminally responsible — for very slight cost over-runs, in building renovations… has failed.

I see that as an impeccably ethical man… getting only the fair and complete process he is due, under our Constitution and the federal rule of law.

[Unlike with every supposed federal project Tangerine 2.0 starts, there is not even a whiff in this one that anyone connected to Mr.Powell benefited from the overrun. These were competitively bid contracts. OTOH, practically every single contract Trump awards is to a close crony of his, and it is a near certainty that some form of kickback or another is being paid back to his campaign coffers.] Yet, John never makes so much as a peep — about any of that.

Sit down, John.

And shut up.